Please login to the form below

Not currently logged in
Email:
Password:

Pfizer generic on hold until 2019

A US district court has ruled against Teva Pharmaceuticals marketing a generic version of Viagra until its Pfizer patent expires in October 2019
A US district court has ruled against Teva Pharmaceuticals marketing a generic version of Viagra until its Pfizer patent expires in October 2019.

Israel-based Teva had claimed Pfizer's patent on Viagra (sildenafil) wasn't valid and couldn't be enforced. It also claimed that Pfizer intentionally withheld documents from the US Patent and Trademark Office.

But US Judge Rebecca Smith, Virginia said that Teva had presented no clear and convincing evidence to support this, in a 110-page opinion.

The decision was made at the end of a two-week non-jury trial. It protects Pfizer's $1bn a year in US Viagra sales.

Pfizer has noted that the decision is subject to appeal. Litigation on the same patent against other companies remains pending.

16th August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics